BC006
/ Adagene, Guilin SanJin Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 05, 2025
Guilin Sanjin: The new indication of BC006 monoclonal antibody injection of the holding subsidiary has been approved for drug clinical trials [Google translation]
(Sina Corp)
- "People's Finance...that Guilin Sanjin...announced on the evening of May 5 that recently, the company's controlling subsidiary Baochuan Biomedicine Technology received the clinical trial approval certificate for BC006 monoclonal antibody injection approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials of the drug for the indication of idiopathic pulmonary fibrosis."
New trial • Idiopathic Pulmonary Fibrosis
1 to 1
Of
1
Go to page
1